Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71

Vor Biopharma Inc. (NASDAQ:VOR) has earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $41.71.

A number of equities analysts have recently commented on VOR shares. Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Wedbush lifted their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VOR. Cannon Global Investment Management LLC acquired a new stake in shares of Vor Biopharma during the 1st quarter valued at $209,000. Sei Investments Co. acquired a new stake in shares of Vor Biopharma during the first quarter valued at about $245,000. Independent Financial Group LLC bought a new stake in shares of Vor Biopharma during the first quarter worth about $249,000. Bollard Group LLC increased its stake in shares of Vor Biopharma by 763.8% in the fourth quarter. Bollard Group LLC now owns 23,987 shares of the company’s stock valued at $314,000 after buying an additional 21,210 shares during the period. Finally, Wellington Management Group LLP bought a new position in Vor Biopharma in the 2nd quarter valued at approximately $499,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Stock Up 3.5%

Shares of Vor Biopharma stock opened at $18.69 on Monday. The company has a 50 day moving average of $22.09 and a 200-day moving average of $17.97. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $39.49.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, equities analysts forecast that Vor Biopharma will post -2.56 earnings per share for the current year.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.